octagam 50 mg/ ml
octapharma (2) - immunglobulin, normalt, humant - infusjonsvæske, oppløsning - 50 mg/ ml
octagam 50 mg/ ml
octapharma (2) - immunglobulin, normalt (humant) - infusjonsvæske, oppløsning - 50 mg/ ml
octagam 100 mg/ ml
octapharma (2) - immunglobulin, normalt, humant - infusjonsvæske, oppløsning - 100 mg/ ml
gammanorm 165 mg/ ml
octapharma ab - immunglobulin, normalt, humant - injeksjonsvæske, oppløsning - 165 mg/ ml
panzyga 100 mg/ ml
octapharma ab - immunglobulin, normalt, humant - infusjonsvæske, oppløsning - 100 mg/ ml
zutectra
biotest pharma gmbh - human hepatitis b immunoglobulin - immunization, passive; hepatitis b; liver transplantation - immune sera og immunglobuliner, - forebygging av hepatitt b-virus (hbv) re-infeksjon hos hbsag og hbv-dna-negative voksne pasienter minst en uke etter levertransplantasjon for hepatitt b-indusert leversvikt. hbv-dna-negativ status bør bekreftes i løpet av de siste 3 månedene før olt. pasienter bør være hbsag-negative før behandlingsstart. samtidig bruk av tilstrekkelig virostatic agenter bør betraktes som standard av hepatitt b re-infeksjon prophylaxis.
cuvitru 200 mg/ ml
baxalta innovations gmbh - immunglobulin, normalt, humant - injeksjonsvæske, oppløsning - 200 mg/ ml
venbig 50 ie/ ml
kedrion s.p.a. - immunglobulin mot hepatitt b, humant - pulver og væske til infusjonsvæske, oppløsning - 50 ie/ ml
hizentra
csl behring gmbh - human normal immunoglobulin (scig) - immunologiske mangelsyndrom - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.
flebogamma dif (previously flebogammadif)
instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.